TMEM86A: A Potential Drug Target and Biomarker for Lysoplasmal Genomics

Target Name: TMEM86A

NCBI ID: G144110

TMEM86A

Other Name(s): Lysoplasmalogenase-like protein TMEM86A | FLJ90119 | transmembrane protein 86A | Transmembrane protein 86A | TM86A_HUMAN

TMEM86A: A Potential Drug Target and Biomarker for Lysoplasmal Genomics

Introduction

TMEM86A, also known as lysoplasmal genomics, is a gene that encodes a protein with significant potential in the field of diseases characterized by lysosomal storage disorders. This gene has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases , and autoimmune disorders.

The Importance of TMEM86A

TMEM86A is a member of the Taur family, a specialized chromatin structure mainly expressed in eukaryotes. The protein encoded by the TMEM86A gene is a lysosomal acidic protein whose main function is to degrade various intracellular and extracellular molecules, such as extracellular vesicles, virus particles, cell debris, etc. Under normal circumstances, lysosomes degrade harmful molecules inside and outside cells through various pathways to maintain a stable physiological environment within cells. However, in certain disease states, lysosomal function is disrupted, leading to accumulation of intracellular molecules, ultimately leading to disease.

As a potential drug target, TMEM86A has been extensively studied for its role in tumors, neurodegenerative diseases, and immune diseases. The relationship between TMEM86A and tumor occurrence, development, metastasis and treatment response has attracted great attention from scientists. Many research teams have begun to explore the use of TMEM86A as a drug target to treat various tumors, especially lung cancer, prostate cancer, and breast cancer.

TMEM86A as a biomarker

In addition to being a drug target, TMEM86A can also serve as a potential biomarker to detect disease progression and treatment efficacy. Since the expression level of TMEM86A changes in various disease states, it can be used as a monitoring indicator of disease progression and treatment effect. By detecting the expression levels of TMEM86A, patients' disease severity and response to drug treatment can be assessed.

Detection of TMEM86A

Currently, multiple methods have been developed to detect the expression level of TMEM86A. Among them, qRT-PCR and Western blotting are the two most commonly used methods.

qRT-PCR

qRT-PCR is a method that amplifies specific genes through PCR to detect their expression levels. In this method, both ends of the TMEM86A gene are designed as primers to generate RNA for the TMEM86A protein through a PCR reaction. Then, RNA levels were detected by qRT-PCR kit to evaluate the expression level of TMEM86A.

Western blotting

Western blotting is a method to evaluate TMEM86A by detecting protein expression levels. In this method, the cDNA of the TMEM86A gene was extracted and amplified by PCR. Subsequently, the protein expression level was detected by Western blotting kit to evaluate the expression level of TMEM86A.

Biological functions of TMEM86A

TMEM86A exhibits biological activity in a variety of disease states. During tumor growth, the expression level of TMEM86A increases, which can increase the invasion and metastasis ability of tumor cells. In neurodegenerative diseases, the expression level of TMEM86A is reduced, leading to nerve cell death and ultimately the progression of the disease. In immune diseases, the expression level of TMEM86A increases, causing immune cells to attack normal tissues in the body and aggravating the symptoms of the disease.

Drug Development of TMEM86A

Based on the potential of TMEM86A as a drug target, scientists have begun to explore the use of TMEM86A as a drug to treat tumors, neurodegenerative diseases, and immune diseases. Currently, TMEM86A has been proven to be useful in treating a variety of tumors, especially lung cancer, prostate cancer, and breast cancer. However, due to changes in the expression levels of TMEM86A in various disease states, the therapeutic efficacy and safety of TMEM86A require further study.

Conclusion

TMEM86A is a gene with significant biological activity and can be used as a potential drug target for the treatment of tumors, neurodegenerative diseases and immune diseases. Currently, a variety of methods have been developed to detect the expression level of TMEM86A and provide a basis for drug development of TMEM86A. However, due to changes in the expression levels of TMEM86A in various disease states, the therapeutic efficacy and safety of TMEM86A require further study.

Protein Name: Transmembrane Protein 86A

The "TMEM86A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMEM86A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets